XML 17 R7.htm IDEA: XBRL DOCUMENT v3.23.3
UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED CONDENSED STATEMENT OF CASH FLOW - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
CASH FLOWS FROM OPERATING ACTIVITIES    
Net income $ 12,349 $ 11,918
Adjustments to reconcile net income to net cash provided by operating activities    
Depreciation 465 454
Amortization 4,824 4,837
Provision for (recovery of) losses on accounts receivable (31) 21
Amortization of Right of Use Assets 39 39
Deferred income taxes (284) (409)
Stock-based compensation expense 153 121
Tax benefit attributable to exercise of stock options 12 0
Changes in operating assets and liabilities    
Accounts receivable and other receivables 2,133 (1,059)
Inventories (925) (2,065)
Prepaid expenses and other current assets 19 (5)
Accounts payable (712) 540
Accrued expenses (1,093) 1,075
Total adjustments 4,600 3,549
Net cash provided by operating activities 16,949 15,467
CASH FLOWS FROM INVESTING ACTIVITIES    
Property and equipment (549) (771)
Intangible assets 0 (9)
Net cash used in investing activities (549) (780)
CASH FLOWS FROM FINANCING ACTIVITIES    
Proceeds from issuance of common stock - options 117 43
Common stock purchased and retired 0 (2,495)
Payment of dividends (3,211) (2,112)
Net cash used in financing activities (3,094) (4,564)
Effect of exchange rate changes on cash (149) (1,586)
Net increase in cash and cash equivalents 13,157 8,537
Cash at beginning of period 75,052 60,974
Cash at end of period 88,209 69,511
Cash paid during the period for income taxes 3,489 3,502
Cash paid during the period for interest $ 0 $ 0